Contact this trialFirst, we need to learn more about you.
Procedure
NUV-868 + Olaparib/Enzalutamide for Cancer
Recruiting1 awardPhase 1 & 2
Denver, Colorado
This trial is testing a new drug, NUV-868, for safety and efficacy in patients with advanced solid tumors. The drug will be taken orally, either as a monotherapy or in combination with other drugs olaparib or enzalutamide, in 28-day cycles. The trial will continue until the disease progresses, there are unacceptable side effects, the patient withdraws consent, or the trial is terminated.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.